13.1 Acute Gastroenteritis, Dehydration Assessment & WHO ORS Protocols

Etiology & Pathophysiology of Acute Diarrhea in Children

Acute gastroenteritis remains one of the leading causes of morbidity and mortality in infants and young children across the Caribbean and globally. Diarrhea is clinically defined as the passage of three or more loose or watery stools within a 24-hour period (or a frequency noticeably greater than normal for the child). Acute diarrhea lasts fewer than 14 days; persistent diarrhea extends between 14 and 29 days; and chronic diarrhea persists for 30 days or longer.

Infectious Etiologies in the Caribbean

1. Viral Pathogens (70% to 80% of Cases):

   • Rotavirus: A double-stranded RNA reovirus historically responsible for the majority of severe, dehydrating infantile diarrhea. It infects and destroys mature, absorptive enterocytes lining the tips of the small intestinal villi, sparing immature crypt cells. The viral non-structural protein 4 (NSP4) acts as an enterotoxin, triggering intracellular calcium release and active chloride secretion. Routine vaccination with pentavalent (RV5) or monovalent (RV1) live-attenuated oral vaccines has dramatically reduced hospitalization rates across Caribbean territories.
   • Norovirus: A positive-sense single-stranded RNA calicivirus, now the leading cause of epidemic and sporadic acute gastroenteritis in vaccinated populations. Characterized by prominent, explosive non-bilious projectile vomiting, watery non-bloody diarrhea, low-grade fever, and crampy abdominal pain following a brief 12-to-48-hour incubation period. Highly contagious via low infectious inocula and environmental stability.
   • Enteric Adenovirus (Serotypes 40/41) & Astrovirus: Cause mild to moderate watery diarrhea and protracted illness lasting 7 to 10 days in young children.

2. Bacterial Pathogens (15% to 20% of Cases):

   • Campylobacter jejuni: Acquired through contaminated poultry, unpasteurized milk, or untreated water. Causes acute inflammatory diarrhea with high fever, severe periumbilical abdominal pain (frequently mimicking acute appendicitis), and stools containing blood and leukocytes. Associated with post-infectious Guillain-Barré syndrome and reactive arthritis.
   • Salmonella enterica (Non-typhoidal): Acquired via undercooked poultry, eggs, or contact with reptilian pets (turtles, iguanas). Produces enterocolitis with nausea, vomiting, fever, and green watery or mucoid stools. In infants under 3 months, immunocompromised children, or patients with sickle cell disease (HbSS)—prevalent across the Caribbean—Salmonella bacteremia can seed bones and joints, causing acute osteomyelitis or septic arthritis.
   • Shigella species (S. sonnei, S. flexneri, S. dysenteriae): Highly virulent organism with an infectious dose as low as 10 to 100 bacilli. Invades colonic enterocytes, causing mucosal microabscesses, intense mucosal inflammation, superficial ulceration, high fever, tenesmus, and the classic clinical syndrome of dysentery (frequent, small-volume stools composed almost entirely of gross blood, mucus, and pus). S. dysenteriae type 1 produces Shiga toxin, precipitating hemolytic uremic syndrome (HUS).
   • Escherichia coli Variants:
     • Enterotoxigenic E. coli (ETEC): Major cause of traveler's diarrhea and infantile watery diarrhea in developing regions. Produces heat-labile (LT) and heat-stable (ST) enterotoxins that stimulate adenylate and guanylate cyclase, respectively, provoking massive, painless, watery secretory diarrhea.
     • Enterohemorrhagic E. coli (EHEC / Shiga toxin-producing E. coli [STEC], e.g., O157:H7): Transmitted via undercooked ground beef or contaminated produce. Causes afebrile or low-grade febrile bloody diarrhea. Antibiotic administration is strictly contraindicated as it stimulates bacterial stress responses and phage lysis, increasing Shiga toxin release and dramatically elevating the risk of Hemolytic Uremic Syndrome (HUS) (triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury).

3. Parasitic Pathogens (5% of Cases):

   • Giardia lamblia (duodenalis): Flagellated protozoan acquired by ingesting cysts from contaminated water sources or daycare centers. Trophozoites adhere to duodenal and jejunal brush border enterocytes, flattening microvilli without tissue invasion. Causes malabsorptive, foul-smelling, pale, greasy, frothy stools, bloating, flatulence, anorexia, and weight loss.
   • Entamoeba histolytica: Causes amebic dysentery with colonic flask-shaped ulcers, trophozoites containing ingested red blood cells, and potential extraintestinal amebic liver abscesses.
   • Cryptosporidium parvum: Intracellular protozoan causing self-limiting watery diarrhea in immunocompetent children, but prolonged, life-threatening choleriform diarrhea in immunocompromised children (e.g., advanced pediatric HIV).

Pathophysiological Classification: Secretory, Osmotic & Invasive

WHO Clinical Dehydration Assessment & Classification

The World Health Organization (WHO) framework classifies dehydration into three categories based on clinical signs that reflect intravascular and interstitial volume depletion. Laboratory measurements (electrolytes, urea, creatinine, blood gas) are not required for initiating treatment and should never delay prompt clinical rehydration.

Clinical Assessment Matrix

WHO Evidence-Based Rehydration Protocols: Plans A, B & C

+-----------------------------------------------------------------------------------------+
|                        WHO THREE-TIER REHYDRATION MANAGEMENT MATRIX                     |
+-----------------------------------------------------------------------------------------+
| PLAN A: NO DEHYDRATION (Home Care)                                                      |
| - Give extra fluids: ORS, clean water, soup, continued frequent breastfeeding           |
| - Oral Zinc: WHO2024 suggests 5 mg/day x 10-14 days in children up to 10 years      |
| - Continue age-appropriate feeding; never dilute milk; review danger signs             |
+-----------------------------------------------------------------------------------------+
| PLAN B: SOME DEHYDRATION (Supervised Clinic Care)                                       |
| - WHO Reduced-Osmolarity ORS: 75 mL/kg administered orally over 4 hours                 |
| - If child vomits, pause 10 minutes, then resume at slower rate (1 spoon every 2-3 min) |
| - Reassess clinical hydration status at 4 hours -> Select Plan A, Plan B, or Plan C     |
+-----------------------------------------------------------------------------------------+
| PLAN C: SEVERE DEHYDRATION (Emergency Inpatient Resuscitation)                          |
| - IV Ringer's Lactate (or 0.9% Normal Saline) total 100 mL/kg:                          |
|   * Infants (< 12 months): 30 mL/kg in 1 hour -> then 70 mL/kg in 5 hours (total 6 h)  |
|   * Older Children (>= 12 months): 30 mL/kg in 30 min -> then 70 mL/kg in 2.5 h (total 3 h)|
| - Give oral ORS (5 mL/kg/h) as soon as child can swallow; reassess every 15-30 minutes  |
+-----------------------------------------------------------------------------------------+

Plan A: Home Management & Prevention of Dehydration

Indicated for children with acute diarrhea who exhibit no signs of dehydration. Managed at home by parents following four essential rules:

1. Provide Extra Fluids: Offer more fluids than usual to replace ongoing losses. After each loose stool, administer: 50 to 100 mL of fluid for children under 2 years of age; 100 to 200 mL of fluid for children 2 years of age and older. Acceptable fluids include WHO ORS solution, clean drinking water, salted rice water, vegetable soups, and continuous breast milk. Avoid commercial fruit juices, sweetened sodas, and sports drinks because their high sucrose/fructose concentration and high osmolarity (> 350-500 mOsm/L) exacerbate osmotic diarrhea.
2. Zinc Supplementation: WHO2024 suggests 5 mg elemental zinc once daily for 10 to 14 days in children up to 10 years with acute watery or persistent diarrhea. This conditional recommendation replaces the previous 10/20 mg age-based dosing.
   • Mechanism: Zinc acts as a potassium channel blocker, stimulates mucosal brush border enzyme synthesis (alkaline phosphatase, disaccharidases), enhances enterocyte regeneration, tightens intercellular junctions, and strengthens cell-mediated immunity. Clinical trials demonstrate zinc reduces diarrhea duration by 25% and cuts subsequent diarrhea episodes over the following 3 months by 30%.
3. Continue Feeding: Never withhold food or dilute formula. Continued enteral nutrition preserves mucosal villous architecture, prevents nutrient malabsorption, and accelerates gut recovery. Provide small, frequent, nutrient-dense meals (cereals, bananas, lean meat, yogurt).
4. Counsel on Danger Signs: Educate caregivers to return immediately to the healthcare facility if the child develops: intractable vomiting (unable to retain any oral intake), increasing lethargy or floppiness, deeply sunken eyes, extreme thirst, fever, or stools containing blood.

Plan B: Oral Rehydration Therapy for Some Dehydration

Indicated for children classified with some/moderate dehydration. Managed under direct clinical observation in a primary healthcare facility or oral rehydration unit over a 4-hour period:

• Dosing: Administer 75 mL/kg of WHO reduced-osmolarity ORS solution over 4 hours (or follow the WHO weight-independent age chart: < 4 months [200-400 mL]; 4-11 months [400-700 mL]; 12-23 months [700-900 mL]; 2-5 years [900-1400 mL]).
• Administration Technique: Teach the caregiver to give ORS using a clean cup or spoon. For infants, deliver 1 teaspoon (5 mL) every 1 to 2 minutes. Frequent small sips are better tolerated than large volumes.
• Management of Emesis: Vomiting is common during early gastroenteritis. If the child vomits, wait 10 minutes to allow gastric irritability to subside, then resume ORS administration at a slightly slower pace (e.g., 1 spoonful every 2 to 3 minutes).
• Breastfeeding: Breastfed infants must continue on-demand breastfeeding throughout the 4-hour rehydration period between sips of ORS.
• Reassessment at 4 Hours:
  • If dehydration has completely resolved: Transition to Plan A; discharge home with ORS packets, zinc, and caregiver education.
  • If signs of some dehydration persist: Repeat Plan B for another 4 hours, introducing small amounts of food/breast milk.
  • If the child has deteriorated into severe dehydration: Transition immediately to Plan C.

Plan C: Emergency Intravenous Resuscitation for Severe Dehydration

Severe dehydration is a medical emergency and can progress to hypovolemic shock; assess perfusion separately. Standard Plan C below is for children without SAM; SAM requires its specific monitored fluid regimen. Immediate intravenous access must be secured; if peripheral cannulation fails within 5 minutes, an intraosseous (IO) needle must be placed into the proximal tibia without delay.

• Fluid Selection: Ringer's Lactate (Hartmann's Solution) is the preferred resuscitation crystalloid because its electrolyte profile closely mimics extracellular fluid and its lactate buffer is metabolized by the liver into bicarbonate, directly correcting metabolic acidosis. If Ringer's Lactate is unavailable, Isotonic 0.9% Normal Saline is an acceptable alternative. Hypotonic solutions (e.g., 5% Dextrose in water, 0.18% or 0.45% saline) are strictly contraindicated for acute volume resuscitation as they produce rapid cerebral edema and fatal hyponatremia.
• Total Volume: 100 mL/kg administered according to the strict WHO age-stratified timeline:

• Monitoring & Transition to Oral Intake:
  • Reassess the child every 15 to 30 minutes. If the radial pulse remains very weak or absent after the initial 30 mL/kg, repeat that volume over the same duration with reassessment before the 70 mL/kg phase. Persistent shock requires urgent senior review of the cause and fluid response.
  • As soon as the child regains full consciousness and can swallow safely (usually after 3 to 4 hours in infants, or after 1 to 2 hours in older children), initiate oral ORS at a rate of 5 mL/kg/hour while the IV infusion continues. Oral intake provides essential potassium and base precursors, stimulating intestinal enterocyte recovery.
  • Upon completion of the full IV regimen (6 hours for infants, 3 hours for older children), fully reassess the child to select Plan A, Plan B, or repeat Plan C.

Biophysical Mechanism & Formulation of WHO Reduced-Osmolarity ORS

Oral Rehydration Therapy (ORT) is hailed as one of the greatest medical breakthroughs of the twentieth century, drastically reducing global under-5 diarrheal mortality. Its success rests upon an elegant cellular physiological mechanism that remains intact despite severe enterotoxin-mediated secretory diarrhea.

The SGLT1 Cotransport Mechanism

The apical brush border membrane of mature small intestinal enterocytes possesses a specialized transport protein: the Sodium-Glucose Cotransporter 1 (SGLT1). SGLT1 couples the transport of two sodium ions (Na+) to one glucose molecule down the electrochemical gradient for sodium into the enterocyte cytoplasm. This gradient is continuously maintained by the basolateral ATP-dependent Na+/K+ ATPase pump, which extrudes sodium into the paracellular space while pumping potassium into the cell.

In cholera and other toxin-mediated secretory diarrheas, bacterial toxins activate adenylate cyclase or guanylate cyclase, elevating intracellular cAMP or cGMP, which opens the CFTR chloride channel and inhibits electroneutral Na+/H+ exchangers. Crucially, the SGLT1 cotransport pathway is completely independent of cyclic nucleotides and remains 100% functional. Sodium and glucose supplied by ORS are absorbed through SGLT1; the solution's equimolar concentrations do not imply a 1:1 transporter stoichiometry. The accumulation of sodium and glucose in the intercellular space creates a powerful osmotic gradient that draws water passively from the gut lumen through paracellular tight junctions and transcellular aquaporin channels back into the systemic circulation.

Formulation Comparison: Reduced-Osmolarity vs Original ORS

In 2002, the WHO and UNICEF revised the standard ORS formula, transitioning from the older citrate-based formulation (311 mOsm/L) to the current reduced-osmolarity ORS (245 mOsm/L).

Evidence-Based Clinical Benefits: Systematic Cochrane reviews confirmed that reduced-osmolarity ORS (245 mOsm/L) produces a 20% to 25% reduction in stool output, a 30% reduction in vomiting episodes, and a 33% reduction in the requirement for unscheduled intravenous fluid infusions compared to the original 311 mOsm/L formulation.

Antimicrobial Stewardship & Pharmacological Contraindications

Strict Indications for Antimicrobial Therapy

Antimicrobial therapy is NOT indicated for the vast majority of children with acute gastroenteritis. Indiscriminate antibiotic prescribing accelerates global antimicrobial resistance, disrupts protective indigenous gut microflora, prolongs Salmonella carrier states, and carries toxic side effects.

Treat selected enteric or systemic infections according to the likely pathogen and local susceptibility. Important indications include:

1. Invasive Bacterial Dysentery: High fever, systemic toxicity, tenesmus, and frequent small stools containing gross blood and mucus (suspected Shigella, severe Campylobacter, or EIEC).
   • First-line: Oral Azithromycin (10 to 12 mg/kg on day 1, followed by 5 mg/kg once daily for 4 days) OR oral Ciprofloxacin (15 mg/kg twice daily for 3 days; benefit outweighs theoretical cartilage toxicity risks in severe dysentery).
   • Second-line: Intravenous Ceftriaxone (50 to 100 mg/kg once daily for 3 to 5 days) for children unable to tolerate oral intake or in toxic septic shock.
2. Cholera with Severe Dehydration, High Purging, Rehydration Failure or High-Risk Comorbidity:
   • First-line: Single-dose oral Azithromycin (20 mg/kg, max 1.0 g) or Doxycycline (2 to 4 mg/kg single dose in children >= 8 years). Reduces duration of diarrhea and fluid requirements.
3. Treatable Protozoal Infection:
   • Persistent diarrhea (> 14 days) with malabsorptive stools and confirmed cysts/trophozoites on microscopy or stool antigen ELISA.
   • Giardiasis Therapy: Oral Metronidazole (15 mg/kg/day divided three times daily for 5–7 days) or Tinidazole (50 mg/kg single dose, max 2 g).
   • Confirmed Amoebic Colitis: Give tissue-active metronidazole or tinidazole, followed by a luminal agent such as paromomycin; treatment must eradicate both invasive disease and intestinal carriage.
4. High-Risk Salmonella Enteritis:
   • While immunocompetent older children with non-typhoidal Salmonella enterocolitis require supportive care only, antibiotics (IV Ceftriaxone or oral Ciprofloxacin) are mandatory for: infants < 3 months of age, children with Sickle Cell Disease (to prevent Salmonella bacteremia and osteomyelitis), severe malnutrition, or systemic bacteremia.

Absolute Contraindications: Antimotility Agents & Antidiarrheals

In Caribbean registration examinations, questions regarding antidiarrheal pharmacotherapy are high-frequency safety checkpoints:

• Antimotility Agents (Loperamide, Diphenoxylate-Atropine): STRICTLY CONTRAINDICATED in all children presenting with acute diarrhea. By paralyzing intestinal smooth muscle, these agents inhibit physiological peristaltic clearance of pathogens and toxins, inducing bacterial translocation, systemic septicemia, toxic megacolon, intestinal perforation, severe paralytic ileus, and fatal central nervous system depression.
• Bismuth Subsalicylate: Contraindicated in children due to mucosal absorption of salicylate and the risk of Reye syndrome (acute encephalopathy with fatty hepatic microvesicular degeneration), particularly during viral influenza or varicella co-infections.
• Adsorbents (Kaolin-pectin, activated charcoal): Ineffective; they may alter stool consistency without reducing actual fluid and electrolyte losses, and they bind essential nutrients, vitamins, and oral medications.

Role of Antiemetics

Routine antiemetic administration is generally discouraged in primary pediatric diarrhea. However, in emergency department settings where persistent non-bilious vomiting prevents successful oral rehydration under Plan B, a single dose of oral ondansetron (0.15 mg/kg, max 8 mg) may be used in children >=6 months after assessment. Avoid it with ileus or congenital long-QT syndrome; assess electrolyte abnormalities and other QT-prolonging risks. Ondansetron (a 5-HT3 receptor antagonist) significantly decreases vomiting, improves the success rate of oral rehydration therapy, and reduces hospital admission rates. Conversely, phenothiazines (promethazine) and dopamine antagonists (metoclopramide) are strictly contraindicated due to severe risks of sedating obtundation, respiratory depression, and acute extrapyramidal dystonic reactions.